Background: Advances in single-cell sequencing provide unprecedented opportunities for clinical examination of circulating tumor cells, cancer stem cells, and other rare cells responsible for disease progression and drug resistance. On the genomic level, single-cell whole exome sequencing (scWES) started to gain popularity with its unique potentials in characterizing mutational landscapes at a single-cell level. Currently, there is little known about the performance of different exome capture kits in scWES. Nextera rapid capture (NXT; Illumina, Inc.) has been the only exome capture kit recommended for scWES by Fluidigm C1, a widely accessed system in single-cell preparation. Results: In this study, we compared the performance of NXT following Fluidigm’s protocol with Agilent SureSelectXT Target Enrichment System (AGL), another exome capture kit widely used for bulk sequencing. We created DNA libraries of 192 single cells isolated from spheres grown from a melanoma specimen using Fluidigm C1. Twelve high-yield cells were selected to perform dual-exome capture and sequencing using AGL and NXT in parallel. After mapping and coverage analysis, AGL outperformed NXT in coverage uniformity, mapping rates of reads, exome capture rates, and low PCR duplicate rates. For germline variant calling, AGL achieved better performance in overlap with known variants in dbSNP and transition-transversion ratios. Using calls from high coverage bulk sequencing from blood DNA as the golden standard, AGL-based scWES demonstrated high positive predictive values, and medium to high sensitivity. Lastly, we evaluated somatic mutation calling by comparing single-cell data with the matched blood sequence as control. On average, 300 mutations were identified in each cell. In 10 of 12 cells, higher numbers of mutations were identified using AGL than NXT, probably caused by coverage depth. When mutations are adequately covered in both AGL and NXT data, the two methods showed very high concordance (93–100% per cell). Conclusions: Our results suggest that AGL can also be used for scWES when there is sufficient DNA, and it yields better data quality than the current Fluidigm’s protocol using NXT.

Keywords:
Single-cell sequencing, Exome capture, Agilent SureSelect, Illumina Nextera, Somatic mutations
1.
Satija R, Farrell JA, Gennert D, Schier AF, Regev A: Spatial reconstruction of single-cell gene expression data. Nat Biotechnol 2015; 33: 495–502.
2.
Eberwine J, Sul JY, Bartfai T, Kim J: The promise of single-cell sequencing. Nat Methods 2014; 11: 25–27.
3.
Hou Y, Song L, Zhu P, Zhang B, Tao Y, Xu X, et al: Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 2012; 148: 873–885.
4.
Xu X, Hou Y, Yin X, Bao L, Tang A, Song L, et al: Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 2012; 148: 886–895.
5.
Navin NE: The first five years of single-cell cancer genomics and beyond. Genome Res 2015; 25: 1499–1507.
6.
Wills QF, Mead AJ: Application of single-cell genomics in cancer: promise and challenges. Hum Mol Genet 2015; 24:R74–R84.
7.
Eirew P, Steif A, Khattra J, Ha G, Yap D, Fa-rahani H, et al: Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 2015; 518: 422–426.
8.
Shalek AK, Satija R, Adiconis X, Gertner RS, Gaublomme JT, Raychowdhury R, Schwartz S, Yosef N, Malboeuf C, Lu D, Trombetta JJ, Gennert D, Gnirke A, Goren A, Hacohen N, Levin JZ, Park H, Regev A: Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature 2013; 498: 236–240.
9.
Molinaro AM, Pearson BJ: In silico lineage tracing through single cell transcriptomics identifies a neural stem cell population in planarians. Genome Biol 2016; 17: 87.
10.
Babayan A, Alawi M, Gormley M, Müller V, Wikman H, McMullin RP, Smirnov DA, Li W, Geffken M, Pantel K, Joosse SA: Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells. Oncotarget 2017; 8: 56066–56080.
11.
Borgstrom E, Paterlini M, Mold JE, Frisen J, Lundeberg J: Comparison of whole genome amplification techniques for human single cell exome sequencing. PLoS One 2017; 12:e0171566.
12.
Chilamakuri CS, Lorenz S, Madoui MA, Vodák D, Sun J, Hovig E, Myklebost O, Meza-Zepeda LA: Performance comparison of four exome capture systems for deep sequencing. BMC Genomics 2014; 15: 449.
13.
Walter C, Pozzorini C, Reinhardt K, Geffers R, Xu Z, Reinhardt D, von Neuhoff N, Hanenberg H: Single-cell whole exome and targeted sequencing in NPM1/FLT3 positive pediatric acute myeloid leukemia. Pediatr Blood Cancer 2018; 65.
14.
Gangavarpu KJ, Huss WJ: Isolation and applications of prostate side population cells based on dye cycle violet efflux. Curr Protoc Toxicol Chapter 2011; 22(Unit 22): 22.
15.
Boiko AD: Isolation of melanoma tumor-initiating cells from surgical tissues. Methods Mol Biol 2013; 961: 253–259.
16.
Li H, Durbin R: Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754–1760.
17.
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R; 1000 Genome Project Data Processing Subgroup: The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078–2079.
18.
McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA: The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297–1303.
19.
Zhu Q, Hu Q, Shepherd L, Wang J, Wei L, Morrison CD, Conroy JM, Glenn ST, Davis W, Kwan ML, Ergas IJ, Roh JM, Kushi LH, Ambrosone CB, Liu S, Yao S: The impact of DNA input amount and DNA source on the performance of whole-exome sequencing in cancer epidemiology. Cancer Epidemiol Biomarkers Prev 2015; 24: 1207–1213.
20.
Edmonson MN, Zhang J, Yan C, Finney RP, Meerzaman DM, Buetow KH: Bambino: a variant detector and alignment viewer for next-generation sequencing data in the SAM/BAM format. Bioinformatics 2011; 27: 865–866.
21.
Wei L, Liu S, Conroy J, Wang J, Papanicolau-Sengos A, Glenn ST: Whole-genome sequencing of a malignant granular cell tumor with metabolic response to pazopanib. Cold Spring Harb Mol Case Stud 2015; 1:a000380.
22.
Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K: dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29: 308–311.
23.
1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA: An integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491: 56–65.
24.
NHLBI E: Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA. (accessed: June 04, 2013).
25.
Wang K, Li M, Hakonarson H: ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010; 38:e164.
26.
Dong X, Zhang L, Milholland B, Lee M, Maslov AY, Wang T, Vijg J: Accurate identification of single-nucleotide variants in whole-genome-amplified single cells. Nat Methods 2017; 14: 491–493.
27.
Hou Y, Wu K, Shi X, Li F, Song L, Wu H: Comparison of variations detection between whole-genome amplification methods used in single-cell resequencing. GigaScience 2015; 4: 37.
28.
Zafar H, Wang Y, Nakhleh L, Navin N, Chen K: Monovar: single-nucleotide variant detection in single cells. Nat Methods 2016; 13: 505–507.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.